Short description
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Description
Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.
Last funding
Cannot Access
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Gaithersburg, Maryland, United States, North America
Founded on
January 1, 2015
Exited on
February 4, 2022
Went public on
February 4, 2022
Stock symbol
ACLX
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccessforu, Blurry Noaccess, Noaccess, Noaccess, No Way, Noway Youcantaccess, Blurry Noaccess, Cannot Access, Blurry Noaccess, No Way, Noaccess, No Way, Nopepepe, Nopepepe, Cannot Access, Noway Youcantaccess, Nopepepe, Noaccess, Absolutely Noaccess, Cannot Access, Nopepepe, Noaccess, Nopepepe, Absolutely Noaccess, Noaccess
Sign in for full access
Founders
David Hilbert